Mount Sinai Hospital, Canada

mountsinai.on.ca

Total trials

153

Active

31

Phase 3

18

Total enrollment

44,867

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Nirmatrelvir/ritonavir1
Remdesivir1
Gradual dose reduction of semaglutide1
Abrupt cessation of semaglutide1
Normal saline3
Ropivacaine1
Acetaminophen1
Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution1
Methoxyflurane - Penthrox1
Start Antibiotics / Continue Antibiotics for treatment of bacteriuria1
Dopamine1
Norepinephrine1
Blood or saliva sample collection1

Next readouts

  • 2025-12-01
  • 2026-01
  • 2026-06-30
  • 2026-07
  • 2027-01
  • 2027-05
  • 2027-09
  • 2028-09

Top conditions

  • Type 2 Diabetes8
  • Crohn Disease6
  • Inflammatory Bowel Diseases6
  • Ulcerative Colitis5
  • Colitis, Ulcerative4
  • Premature Birth4
  • Influenza4
  • Pain4

Frequently asked questions about Mount Sinai Hospital, Canada

How many clinical trials does Mount Sinai Hospital, Canada have on ClinicalTrials.gov?
Mount Sinai Hospital, Canada is listed as the lead sponsor on 153 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
How many of Mount Sinai Hospital, Canada's trials are in Phase 3?
18 of Mount Sinai Hospital, Canada's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does Mount Sinai Hospital, Canada focus on?
Mount Sinai Hospital, Canada's most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes, Crohn Disease, Inflammatory Bowel Diseases, Ulcerative Colitis, Colitis, Ulcerative.
When are Mount Sinai Hospital, Canada's next clinical trial readouts?
Mount Sinai Hospital, Canada has 8 upcoming primary-completion readouts tracked here; the soonest is “Methoxyflurane for IUD Insertion and Endometrial Biopsy”, expected around 2025-12-01.